ES2179551T3 - Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn. - Google Patents

Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn.

Info

Publication number
ES2179551T3
ES2179551T3 ES98965783T ES98965783T ES2179551T3 ES 2179551 T3 ES2179551 T3 ES 2179551T3 ES 98965783 T ES98965783 T ES 98965783T ES 98965783 T ES98965783 T ES 98965783T ES 2179551 T3 ES2179551 T3 ES 2179551T3
Authority
ES
Spain
Prior art keywords
neurodermitis
crohn
psoriasis
disease
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98965783T
Other languages
English (en)
Inventor
Rajendra K Joshi
Hans-Peter Strebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen International GmbH
Original Assignee
Fumapharm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm AG filed Critical Fumapharm AG
Application granted granted Critical
Publication of ES2179551T3 publication Critical patent/ES2179551T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Uso de uno o varios alquilfumaratos de hidrógeno de fórmula general **(Fórmula)** donde R es un alquilo C1-5, opcionalmente en mezcla con dialquilfumarato de fórmula **(Fórmula)** y opcionalmente coadyuvantes y vehículos farmacéuticos convencionales para la elaboración de una preparación farmacéutica en forma de microcomprimidos o microgránulos para el tratamiento de la psoriasis, la artritis psoriática, la neurodermitis y la enfermedad de Crohn.
ES98965783T 1998-03-31 1998-12-08 Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn. Expired - Lifetime ES2179551T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19814358A DE19814358C2 (de) 1998-03-31 1998-03-31 Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn

Publications (1)

Publication Number Publication Date
ES2179551T3 true ES2179551T3 (es) 2003-01-16

Family

ID=7863089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98965783T Expired - Lifetime ES2179551T3 (es) 1998-03-31 1998-12-08 Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn.

Country Status (25)

Country Link
US (1) US6277882B1 (es)
EP (1) EP1059920B1 (es)
JP (1) JP3527890B2 (es)
CN (1) CN1150898C (es)
AT (1) ATE219936T1 (es)
AU (1) AU745281B2 (es)
BG (1) BG64744B1 (es)
BR (1) BRPI9815772B8 (es)
CA (1) CA2283915C (es)
CZ (1) CZ291788B6 (es)
DE (2) DE19814358C2 (es)
DK (1) DK1059920T3 (es)
EE (1) EE04702B1 (es)
ES (1) ES2179551T3 (es)
HU (1) HU228848B1 (es)
IL (1) IL136835A (es)
NO (1) NO327750B1 (es)
NZ (1) NZ505341A (es)
PL (1) PL191803B1 (es)
PT (1) PT1059920E (es)
RS (1) RS49658B (es)
RU (1) RU2197233C2 (es)
SK (1) SK285187B6 (es)
TR (1) TR200001829T2 (es)
WO (1) WO1999049858A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
HU230252B1 (hu) 2001-01-12 2015-11-30 Biogen Idec International Gmbh Fumársav-amid származékok
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
SI1663197T1 (sl) * 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
ATE455783T1 (de) * 2005-07-07 2010-02-15 Aditech Pharma Ag Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
EP1915334A2 (en) * 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20080299196A1 (en) * 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
SI2139467T1 (sl) * 2007-02-08 2017-01-31 Biogen Ma Inc. Zaščita živčevja pri demielinizacijskih obolenjih
EP2680006A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
HRP20140640T1 (hr) * 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
WO2010079222A1 (en) 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
SMT201800098T1 (it) 2011-06-08 2018-03-08 Biogen Ma Inc Processo per la preparazione di dimetilfumarato cristallino e con purezza elevata
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
NZ627980A (en) * 2012-02-07 2016-12-23 Biogen Ma Inc Pharmaceutical compositions containing dimethyl fumarate
MX2014009511A (es) 2012-02-07 2014-10-24 Xenoport Inc Compuestos de fumarato de morfolinoalquilo, composiciones farmaceuticas y metodos de uso.
KR101449114B1 (ko) * 2012-08-21 2014-10-13 바이오스펙트럼 주식회사 푸마르산을 유효성분으로 포함하는 항염 조성물
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
BR112015022854A2 (pt) 2013-03-14 2017-07-18 Alkermes Pharma Ireland Ltd pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016531912A (ja) 2013-08-26 2016-10-13 フォーワード・ファルマ・アクティーゼルスカブＦｏｒｗａｒｄ Ｐｈａｒｍａ Ａ／Ｓ 低１日用量で投与するためのフマル酸ジメチルを含む医薬組成物
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US20150079180A1 (en) 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
BR112017004708A2 (pt) * 2014-09-12 2017-12-05 Tobira Therapeutics Inc terapia de combinação de cenicriviroc para o tratamento de fibrose
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
HUE055210T2 (hu) 2015-02-08 2021-11-29 Alkermes Pharma Ireland Ltd Monometilfumarát prodrug készítmények
EP3273951B1 (en) 2015-03-27 2020-07-29 Symbionyx Pharmaceuticals Inc. Compositions and methods for treating psoriasis
WO2017060420A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
CN105496804A (zh) * 2015-12-25 2016-04-20 知识产权全资有限公司 用于处理头发以及治疗头部牛皮藓的配方及其试剂盒和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE3127432A1 (de) * 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) * 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE8714143U1 (de) * 1987-10-23 1988-03-24 Werler Kunststoffwerke GmbH & Co, 4760 Werl Sitz- und/oder Liegemöbel
DE3834794A1 (de) * 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
AU1271592A (en) * 1991-01-18 1992-08-27 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
US5407772A (en) * 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
US5972363A (en) * 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition

Also Published As

Publication number Publication date
US6277882B1 (en) 2001-08-21
CN1150898C (zh) 2004-05-26
DE19814358A1 (de) 1999-10-07
PL191803B1 (pl) 2006-07-31
DK1059920T3 (da) 2002-10-14
NO20002872D0 (no) 2000-06-06
CA2283915C (en) 2002-12-03
EP1059920A1 (de) 2000-12-20
IL136835A (en) 2005-05-17
AU745281B2 (en) 2002-03-21
JP3527890B2 (ja) 2004-05-17
DE19814358C2 (de) 2002-01-17
CA2283915A1 (en) 1999-09-30
BG104566A (en) 2001-01-31
AU2159399A (en) 1999-10-18
WO1999049858A1 (de) 1999-10-07
RS49658B (sr) 2007-09-21
BRPI9815772B8 (pt) 2021-07-06
SK285187B6 (sk) 2006-08-03
NO20002872L (no) 2000-06-06
CZ291788B6 (cs) 2003-05-14
IL136835A0 (en) 2001-06-14
ATE219936T1 (de) 2002-07-15
NO327750B1 (no) 2009-09-14
EP1059920B1 (de) 2002-07-03
RU2197233C2 (ru) 2003-01-27
DE59804704D1 (de) 2002-08-08
JP2002509883A (ja) 2002-04-02
EE04702B1 (et) 2006-10-16
NZ505341A (en) 2002-04-26
HU228848B1 (en) 2013-06-28
EE200000440A (et) 2001-12-17
HUP0103234A3 (en) 2003-11-28
BG64744B1 (bg) 2006-02-28
HUP0103234A2 (hu) 2002-01-28
BRPI9815772B1 (pt) 2016-02-10
PL341240A1 (en) 2001-03-26
CN1284870A (zh) 2001-02-21
SK7922000A3 (en) 2001-01-18
YU32000A (sh) 2002-03-18
HK1035134A1 (en) 2001-11-16
BRPI9815772A (pt) 2000-11-21
PT1059920E (pt) 2002-11-29
TR200001829T2 (tr) 2000-11-21
CZ20003086A3 (cs) 2000-11-15

Similar Documents

Publication Publication Date Title
ES2179551T3 (es) Uso de alquilfumaratos de hidrogeno para el tratamiento de la psoriasis, la artritis psoriatica, la neurodermitis y la enfermedad de crohn.
ATE246681T1 (de) Sulfonamide
PA8547001A1 (es) Champues con alcohol behenil
GR3033846T3 (en) Imidazopyridines and their use in treating gastrointestinal diseases.
ATE290015T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
GR3036642T3 (en) Novel benzoyl guanidines, their production and their use in medicaments
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
ATE175669T1 (de) Sulfonylaminopyrimidine, ihre herstellung und verwendung als heilmittel
LU91223I2 (fr) Ivabradine et ses dérivés pharmaceutiquement acceptables (procoralan)
FI931250A0 (fi) Sulfonamido- och sulfonamidokarbonyl-pyridin-2-karboxylsyraamider och deras pyridin-n-oxider, foerfarande foer deras framstaellning och deras anvaendning som laekemedel
EP0735819A4 (en) NEW CRYPTOPHYCINE
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
MY117090A (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
TR200400228T4 (tr) Psöryazinin tedavisinde kullanılacak maddeler
ATE200672T1 (de) Alkoxyalkylcarbamate von imidazo(1,2-a)pyridinen
ITMI922331A1 (it) Uso di paratormone, suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
BG103558A (en) Sulphonic acid or sulphonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
CO4230037A1 (es) Composicion para aplicacion topica a la piel y/o cabello a base de tensioactivo de fosfato y co-tensioactivo
BR1100143A (pt) Composto, e, composição farmacêutica.
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
ES2125354T3 (es) Composicion a base de tandospirona o de sus analogos.
ITRM910430A1 (it) Composizioni farmaceutiche di somatostatina con assorbimento migliorato, loro preparazione e loro impiego
SE9504662D0 (sv) New compounds
EP0291269A3 (en) Anti-tumour sulfonyl urea derivatives